| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease
|
Eastham, James A
|
|
2003
|
62 |
S |
p. 55-62
8 p.
|
article
|
| 2 |
Hormonal therapy options for patients with a rising prostate-specific antigen level after primary treatment for prostate cancer
|
Hellerstedt, Beth
|
|
2003
|
62 |
S |
p. 79-86
8 p.
|
article
|
| 3 |
Introduction
|
Pienta, Kenneth J.
|
|
2003
|
62 |
S |
p. 1-
1 p.
|
article
|
| 4 |
Molecular markers to identify patients at risk for recurrence after primary treatment for prostate cancer
|
Kumar-Sinha, Chandan
|
|
2003
|
62 |
S |
p. 19-35
17 p.
|
article
|
| 5 |
Novel approaches to treat asymptomatic, hormone-naive patients with rising prostate-specific antigen after primary treatment for prostate cancer
|
Dawson, Nancy A
|
|
2003
|
62 |
S |
p. 102-118
17 p.
|
article
|
| 6 |
Novel approaches to treating the asymptomatic hormone-refractory prostate cancer patient
|
Gulley, James
|
|
2003
|
62 |
S |
p. 147-154
8 p.
|
article
|
| 7 |
Phase 3 randomized trial evaluating second-line hormonal therapy versus docetaxel-estramustine combination chemotherapy on progression-free survival in asymptomatic patients with a rising prostate-specific antigen level after hormonal therapy for prostate cancer: an Eastern Cooperative Oncology Group (E1899), intergroup/clinical trials support unit study
|
Walczak, Janet R
|
|
2003
|
62 |
S |
p. 141-146
6 p.
|
article
|
| 8 |
Prostate-specific antigen doubling time and survival in patients with advanced metastatic prostate cancer
|
Loberg, Robert D
|
|
2003
|
62 |
S |
p. 128-133
6 p.
|
article
|
| 9 |
Prostate-specific antigen doubling time in the identification of patients at risk for progression after treatment and biochemical recurrence for prostate cancer
|
Cannon Jr, Glenn M
|
|
2003
|
62 |
S |
p. 2-8
7 p.
|
article
|
| 10 |
Radiation Therapy Oncology Group P-0014: a phase 3 randomized study of patients with high-risk hormone-naive prostate cancer: androgen blockade with 4 cycles of immediate chemotherapy versus androgen blockade with delayed chemotherapy
|
Pienta, Kenneth J
|
|
2003
|
62 |
S |
p. 95-101
7 p.
|
article
|
| 11 |
Role of secondary hormonal therapy in the management of recurrent prostate cancer
|
Ryan, Charles J
|
|
2003
|
62 |
S |
p. 87-94
8 p.
|
article
|
| 12 |
Salvage prostatectomy in patients who have failed radiation therapy or cryotherapy as primary treatment for prostate cancer
|
Chen, Bert T
|
|
2003
|
62 |
S |
p. 69-78
10 p.
|
article
|
| 13 |
Salvage radiotherapy in the treatment of prostate cancer
|
Tsien, Christina
|
|
2003
|
62 |
S |
p. 63-68
6 p.
|
article
|
| 14 |
The patient with hormone-refractory prostate cancer: determining who, when, and how to treat
|
Kent, Elizabeth C
|
|
2003
|
62 |
S |
p. 134-140
7 p.
|
article
|
| 15 |
Use of neoadjuvant and adjuvant therapy to prevent or delay recurrence of prostate cancer in patients undergoing radiation treatment for prostate cancer
|
Pisansky, Thomas M
|
|
2003
|
62 |
S |
p. 36-45
10 p.
|
article
|
| 16 |
Use of neoadjuvant and adjuvant therapy to prevent or delay recurrence of prostate cancer in patients undergoing surgical treatment for prostate cancer
|
Gomella, Leonard G
|
|
2003
|
62 |
S |
p. 46-54
9 p.
|
article
|
| 17 |
Use of nomograms for predicting survival in patients with castrate prostate cancer
|
Galsky, Matt
|
|
2003
|
62 |
S |
p. 119-127
9 p.
|
article
|
| 18 |
Use of nomograms to predict the risk of disease recurrence after definitive local therapy for prostate cancer
|
Diblasio, Christopher J
|
|
2003
|
62 |
S |
p. 9-18
10 p.
|
article
|
Journal description